PAR-1 antagonists for use in the treatment or prevention of influenza virus type A infections
AssigneeInstitut National de la Recherche Agronomique
InventorsBéatrice Riteau, Khaled Khoufache
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and compositions (such as pharmaceutical compositions) comprising PAR1 antagonists for treating or preventing influenza virus type A infections, in particular H1N1 infection. PAR1 antagonists may be combined with a PAR2 agonist.
Claims6
A method of treating an influenza virus type A infection which comprises administration of a therapeutically effective amount of at least one Protease-Activated Receptor-1 (PAR-1) antagonist to a subject, wherein said at least one PAR-1 antagonist is N3-cyclopropyl-7-{[4-(1-methylethyl)phenyl]methyl}-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine.
Dependencies are inferred from the claim text.